Why the study?
Highly effective oncology agents such as anthracyclines and trastuzumab increase the risk of cardiac events, necessitating strategies to maximize benefits while reducing cardiac risk.
Answers are grounded in this paper and cite their sources.
Highlights the need for strategies in risk detection and management to reduce cardiac toxicity in patients receiving highly effective oncology agents.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Leonard Steingo (2017) conducted a review in Malignancy with risk of cardiovascular complications. Chemotherapy (anthracyclines, trastuzumab, novel biologic therapies) was evaluated on Cardiac events and toxicity.
Synapse has enriched 10 related papers. Consider them for comparative context: